DeepHealth vs Qure.ai

For a US hospital building a lung nodule pathway, Qure.ai has the clearer record. qXR-LN (K231805, December 2023) is cleared for radiologists, pulmonologists and ER physicians reading adult frontal chest radiographs, qCT LN Quant (K240740) covers nodule volumetry and tracking, and qCT Lung (K261517) followed in September 2026. Qure's TB use rests on a WHO endorsement the vendor dates to 2021 and on CE marking, and none of its ten FDA records is a TB product. An independent evaluation of 12 TB solutions measured qXR v3 at 95.5% sensitivity and 48.7% specificity at a single threshold. DeepHealth is the weaker pick in the lung pathway: its lung product traces to Aidence's Veye Lung Nodules and its FDA status is not stated. Its Gleamer products include ChestView US, with FDA decisions in February 2025 and September 2026, and the outpatient network that screens breasts and also reads bone and chest films is its buyer.